Dr Reddy’s Laboratories failed to cheer the market despite June quarter net profit doubling. Analysts see concern over the US business and pressure on operating performance as key drags. These concerns have prompted traders to build bearish bets on the stock. Chandan Taparia, derivative analyst at Motilal Oswal, said the weakness could continue and the stock could drift down to Rs 3,950.
Global Markets | European shares fall again as Mideast war drags on
European shares extended their decline on Tuesday, mirroring a global equity selloff as investors grappled with the prospect of a prolonged Middle East conflict. A
March 3, 2026